Lou Brundin

Lou Brundin

Auto-generated profile, based on publicly available information

Lou Brundin

Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ABAshley H Beecham
Ashley H Beecham
NPNikolaos A Patsopoulos
Nikolaos A Patsopoulos
DXDionysia K Xifara
Dionysia K Xifara
MDMary F Davis
Mary F Davis
AKAnu Kemppinen
Anu Kemppinen
JMJacob McCauley
Jacob McCauley
The International Multiple Sclerosis Genetics Consortium reports the discovery of 48 new susceptibility variants for multiple sclerosis through targeted follow-up of immune-related loci. They also report fine mapping of association signals at established susceptibility loci and provide insights into the immune system processes underlying this disease. Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 potentially associated regions (P < 1.0 × 10−4). In a replication phase, we combined these data with previous genome-wide association study (GWAS) data from an independent 14,802 subjects with multiple sclerosis and 26,703 healthy controls. In these 80,094 individuals of European ancestry, we identified 48 new susceptibility variants (P < 5.0 × 10−8), 3 of which we found after conditioning on previously identified variants. Thus, there are now 110 established multiple sclerosis risk variants at 103 discrete loci outside of the major histocompatibility complex. With high-resolution Bayesian fine mapping, we identified five regions where one variant accounted for more than 50% of the posterior probability of association. This study enhances the catalog of multiple sclerosis risk variants and illustrates the value of fine mapping in the resolution of GWAS signals.

1 September 2019 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
CBClaire Bridel
Claire Bridel
WWWessel N. van Wieringen
Wessel N. van Wieringen
HZHenrik Zetterberg
Henrik Zetterberg
BTBetty M. Tijms
Betty M. Tijms
CTCharlotte E. Teunissen
Charlotte E. Teunissen
EWEdward Wild
Edward Wild
Identifying neuroaxonal damage and quantifying the intensity of this process is a critical step in patient care because it may support diagnosis and help estimate the prognosis of neurological conditions. In addition, it is essential for the evaluation of drug candidates with disease-modifying potential. Neurofilament light protein (NfL) is an abundant cytoskeletal protein exclusively expressed by central and peripheral neurons. Elevated levels of NfL in cerebrospinal fluid (CSF) were first reported in neurodegenerative conditions more than 20 years ago,1 sparking interest in the potential of this neuron-specific protein as a biomarker. Since then, elevated levels of NfL in CSF (cNfL) have been described in a number of neurological and psychiatric conditions. The magnitude of the increase in inflammatory, degenerative, infectious, ischemic, and traumatic neurological conditions, as well as in psychiatric disorders, varies between conditions and studies. To date, cNfL levels have not been compared systematically between neurological disorders, and patient numbers in individual studies are often low. A positive association between cNfL and age has been reported in healthy controls (HC)2 but was not systematically investigated in neurological conditions and may alter the performance of this biomarker across age categories. Together, these questions limit clinical implementation of cNfL. To compare cNfL levels between diagnoses, assess the association of age and sex with these variables, and evaluate the potential of cNfL level as a diagnostic biomarker, we performed a systematic review and meta-analysis on individual data collected from studies reporting cNfL levels in diseases and controls.

1 November 2014 in Cell
Verified
Journal Article
Closed access
MYMaggie S.Y. Yeung
Maggie S.Y. Yeung
SZSofia Zdunek
Sofia Zdunek
OBOlaf Bergmann
Olaf Bergmann
SBSamuel Bernard
Samuel Bernard
MSMehran Salehpour
Mehran Salehpour
JFJonas Frisén
Jonas Frisén

23 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
MYMaggie S. Y. Yeung
Maggie S. Y. Yeung
MDMehdi Djelloul
Mehdi Djelloul
ESEmbla Steiner
Embla Steiner
SBSamuel Bernard
Samuel Bernard
MSMehran Salehpour
Mehran Salehpour
JFJonas Frisén
Jonas Frisén

6 December 2010 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
MKMohsen Khademi
Mohsen Khademi
IKIngrid Kockum
Ingrid Kockum
MAMagnus L Andersson
Magnus L Andersson
EIEllen Iacobaeus
Ellen Iacobaeus
LBLou Brundin
Lou Brundin
TOTomas Olsson
Tomas Olsson
Background: Levels of CXCL13, a potent B-cell chemoattractant, are elevated in the cerebrospinal fluid (CSF) during multiple sclerosis (MS) and are associated with markers of MS activity. Levels decrease upon effective treatments.

17 September 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DDDavid O. Dias
David O. Dias
JKJannis Kalkitsas
Jannis Kalkitsas
YKYildiz Kelahmetoglu
Yildiz Kelahmetoglu
CECynthia P. Estrada
Cynthia P. Estrada
JTJemal Tatarishvili
Jemal Tatarishvili
CGChristian Göritz
Christian Göritz
Fibrotic scar tissue limits central nervous system regeneration in adult mammals. The extent of fibrotic tissue generation and distribution of stromal cells across different lesions in the brain and spinal cord has not been systematically investigated in mice and humans. Furthermore, it is unknown whether scar-forming stromal cells have the same origin throughout the central nervous system and in different types of lesions. In the current study, we compared fibrotic scarring in human pathological tissue and corresponding mouse models of penetrating and non-penetrating spinal cord injury, traumatic brain injury, ischemic stroke, multiple sclerosis and glioblastoma. We show that the extent and distribution of stromal cells are specific to the type of lesion and, in most cases, similar between mice and humans. Employing in vivo lineage tracing, we report that in all mouse models that develop fibrotic tissue, the primary source of scar-forming fibroblasts is a discrete subset of perivascular cells, termed type A pericytes. Perivascular cells with a type A pericyte marker profile also exist in the human brain and spinal cord. We uncover type A pericyte-derived fibrosis as a conserved mechanism that may be explored as a therapeutic target to improve recovery after central nervous system lesions.